The Yale Journal of Biology and Medicine最新文献_第2页

Challenges in Maximizing Impacts of Preventive Strategies against Respiratory Syncytial Virus (RSV) Disease in Young Children. 最大化幼儿呼吸道合胞病毒(RSV)疾病预防策略影响的挑战。

IF 2.7

The Yale Journal of Biology and Medicine Pub Date : 2022-06-30 eCollection Date: 2022-06-01

Zhe Zheng

引用次数: 0

Shoulder Pain and Injury after COVID-19 Vaccination. COVID-19疫苗接种后的肩部疼痛和损伤。

IF 2.7

The Yale Journal of Biology and Medicine Pub Date : 2022-06-30 eCollection Date: 2022-06-01

Dipit Sahu

{"title":"Shoulder Pain and Injury after COVID-19 Vaccination.","authors":"Dipit Sahu","doi":"","DOIUrl":"","url":null,"abstract":"Shoulder injury related to vaccine administration (SIRVA) is a term given to describe shoulder pain and dysfunction arising within 48 hours after vaccine administration and lasting for more than one week. While SIRVA is most commonly seen after influenza and tetanus vaccines, there have been a few recent case reports describing SIRVA-like symptoms after COVID-19 vaccine administration. Two patients presented to the shoulder surgeon's practice center with complaints of shoulder stiffness and pain following the COVID-19 vaccine. The first patient was a 33-year-old man; he presented within 2 days of onset of the pain and 14 days from the vaccine date. He had a complete restriction of shoulder motion (0° flexion, and no external or internal rotation) at presentation. This patient was treated with non-steroidal anti-inflammatory drugs (NSAID) and rested in a sling for a week. The second patient was a 53-year-old woman; she presented with a 6-week duration of mild restriction of active shoulder motion and shoulder pain. Her magnetic resonance imaging (MRI) revealed the presence of subacromial-subdeltoid bursitis. She was treated with subacromial steroid injection and range of motion shoulder exercises. Both patients recovered a near-normal range of motion recovery within a month, and their pain improved significantly. The main lessons from this case report were: (1) patients presenting with a recent increase in pain and acute loss of shoulder movements after vaccination may be managed conservatively with rest and NSAID medications and (2) in case of a subacromial-subdeltoid bursitis in the MRI, subacromial injection of steroid may provide good pain relief.","PeriodicalId":392036,"journal":{"name":"The Yale Journal of Biology and Medicine","volume":" ","pages":"217-220"},"PeriodicalIF":2.7,"publicationDate":"2022-06-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/32/8f/yjbm_95_2_217.PMC9235265.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40579642","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Embracing the Diversity of Latinx Communities to Promote Vaccinations. 拥抱拉丁裔社区的多样性以促进疫苗接种。

IF 2.7

The Yale Journal of Biology and Medicine Pub Date : 2022-06-30 eCollection Date: 2022-06-01

Alexander C Ortiz, Kathleen M Akgün, Isabel S Bazan

引用次数: 0

Healthcare Economics of a Coronavirus Disease 2019 Pop-Up Vaccination Center. 2019冠状病毒疾病的医疗保健经济学弹出式疫苗接种中心。

IF 2.7

The Yale Journal of Biology and Medicine Pub Date : 2022-06-30 eCollection Date: 2022-06-01

Dennis L Caruana, Ryan J Dunn, Sunil K Dhuper, Anthony M Szema

{"title":"Healthcare Economics of a Coronavirus Disease 2019 Pop-Up Vaccination Center.","authors":"Dennis L Caruana, Ryan J Dunn, Sunil K Dhuper, Anthony M Szema","doi":"","DOIUrl":"","url":null,"abstract":"Introduction: Creation of pop-up vaccination sites at trusted community locations has been encouraged to address vaccine hesitancy and provide equitable access to COVID-19 vaccination in minority communities. This study sought to study the healthcare economics of a community-based COVID-19 pop-up vaccination center in terms of the following: costs associated with operating the vaccination center, analysis of billing data from patients who received the Moderna COVID-19 vaccine, and costs of hospitalization for COVID-19 which may be avoided with widespread vaccination. Methods: The pop-up vaccination center was located in Port Jefferson Station, NY, USA. Costs associated with operation of the COVID-19 pop-up vaccination center were quantified, itemized, and tabulated. Current Procedural Technology codes were used to identify patients who received the Moderna COVID-19 vaccine. Billing data were quantified for the cohort as well as per each patient to receive the vaccine. Costs associated with provision of urgent care, emergency, and hospital services to patients with COVID-19 were obtained. Results: The total cost to operate the vaccination center was $25,880. The vaccination center administered the initial dose of the Moderna COVID-19 vaccine to N=251 patients between March and May, 2021. The standard hospital costs for patients admitted to the medical ICU due to COVID-19 ranged from $8,913 to $190,714, per patient. Conclusion: Since the Moderna COVID-19 vaccine series is effective in preventing hospitalization for 93% of patients, this community-based vaccination center's administration of the vaccine series to 240 patients meant aversion of hospitalization due to COVID-19 related morbidity for 223 patients. Therefore, the true impact of this vaccination center, measured in averted hospital costs, ranges from $1,987,599 to $42,529,222.","PeriodicalId":392036,"journal":{"name":"The Yale Journal of Biology and Medicine","volume":" ","pages":"191-197"},"PeriodicalIF":2.7,"publicationDate":"2022-06-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/f8/24/yjbm_95_2_191.PMC9235266.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40558885","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Erratum: The Social Value of Implementing the Ten Steps to Successful Breastfeeding in an Indonesian Hospital: A Case Study. 更正:在印度尼西亚医院实施成功母乳喂养的十个步骤的社会价值:案例研究。

IF 2.7

The Yale Journal of Biology and Medicine Pub Date : 2022-06-30 eCollection Date: 2022-06-01

引用次数: 0

Achieving Global Vaccine Equity: The Case for an International Pandemic Treaty. 实现全球疫苗公平:制定国际大流行病条约的理由。

IF 2.7

The Yale Journal of Biology and Medicine Pub Date : 2022-06-30 eCollection Date: 2022-06-01

Nancy S Jecker

引用次数: 0

Erythema Multiforme Following Hepatitis A and Pneumococcal Vaccinations. 甲型肝炎和肺炎球菌疫苗接种后的多形性红斑。

IF 2.7

The Yale Journal of Biology and Medicine Pub Date : 2022-06-30 eCollection Date: 2022-06-01

Eli Hernandez Quiroz, Catharine Lisa Kauffman, Agnieszka Kupiec-Banasikowska

引用次数: 0

Distorted Human Decision-Making as a Critical Aspect of Pandemic Planning and Preparedness. 扭曲的人类决策是大流行规划和防范的一个关键方面。

IF 2.7

The Yale Journal of Biology and Medicine Pub Date : 2022-06-30 eCollection Date: 2022-06-01

Caroline M Poland, Tamar Ratishvili, Gregory A Poland

引用次数: 0

Trends in the Cost and Utilization of Omalizumab in the Medicare Population: 2013-2017. 奥马利单抗在医保人群中的成本和使用趋势:2013-2017。

IF 2.7

The Yale Journal of Biology and Medicine Pub Date : 2022-06-30 eCollection Date: 2022-06-01

Shayan Cheraghlou, Nelson Ugwu, Beverly Yu, Jeffrey M Cohen

{"title":"Trends in the Cost and Utilization of Omalizumab in the Medicare Population: 2013-2017.","authors":"Shayan Cheraghlou, Nelson Ugwu, Beverly Yu, Jeffrey M Cohen","doi":"","DOIUrl":"","url":null,"abstract":"Background: Omalizumab has been demonstrated to be effective in treating chronic spontaneous urticaria (CSU) and was FDA approved for this indication in 2014. Previous work has shown that access to injectable biologics varies across US counties. In the present study we evaluate geographic and temporal trends in the utilization of omalizumab in the Medicare population by dermatologists, with its use by allergists and pulmonologists as comparators. Methods: We analyzed year-over-year trends in omalizumab utilization across geographic regions using the Medicare Provider Utilization and Payment Data: Part D files. Results: Utilization of omalizumab by dermatologists increased rapidly after its FDA approval, from 0.08 claims/100,000 enrollees totaling $209/100,000 enrollees in 2014 to 1.45 claims/100,000 enrollees totaling $3115/100,000 enrollees in 2017. Nonetheless, prescribing dermatologists were present in only 2.8% (95% Confidence Interval (CI): 2.0%-3.9%) and 0.2% (95% CI: 0.0%-0.5%) of metropolitan and non-metropolitan counties, respectively, in 2017, demonstrating limited availability, especially in non-metropolitan counties. Similarly, prescribers of any specialty were available in 32.9% (95% CI: 30.2%-35.6%) and 3.8% (95% CI: 3.1%-4.8%) of metropolitan and non-metropolitan counties, respectively, in 2017. Conclusions: Our data suggest that despite increasing omalizumab utilization, there remains a lack of access across many counties, particularly in non-metropolitan regions. Efforts to expand omalizumab prescriber accessibility in these counties may improve outcomes for patients with CSU.","PeriodicalId":392036,"journal":{"name":"The Yale Journal of Biology and Medicine","volume":" ","pages":"207-212"},"PeriodicalIF":2.7,"publicationDate":"2022-06-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/3a/31/yjbm_95_2_207.PMC9235260.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40579637","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

COVID-19 Vaccine Hesitancy in Israel Immediately Before the Vaccine Operation. 在疫苗运作前，以色列对COVID-19疫苗的犹豫。

IF 2.7

The Yale Journal of Biology and Medicine Pub Date : 2022-06-30 eCollection Date: 2022-06-01

Sharon Teitler-Regev, Shlomit Hon-Snir

{"title":"COVID-19 Vaccine Hesitancy in Israel Immediately Before the Vaccine Operation.","authors":"Sharon Teitler-Regev, Shlomit Hon-Snir","doi":"","DOIUrl":"","url":null,"abstract":"The development of a vaccine for COVID-19 presented hope for a way out of the global crisis caused by the virus. However, a potential barrier may be vaccine hesitancy, and identifying the factors that affect it is critical, especially concerning a new vaccine technology. The purpose of this research is to identify the factors that effects vaccine hesitancy by using a holistic view. The data were collected from 504 people in December 2020, 3 days before the vaccine operation started in Israel. The analysis included three categories of determinants: (1) contextual influences; (2) health records; and (3) perceived health attitudes. The results indicate that different sets of variables affect willingness to accept the vaccine among the whole spectrum of the vaccine-hesitant and the undecided subsample. In the full sample, gender, age, income, influenza vaccine, perceived trust, perceived susceptibility, perceived benefits, and perceived barriers affected vaccine acceptance. The perceived level of suffering from COVID-19 was associated with willingness to vaccinate, and when religious beliefs increased, the intention to vaccinate decreased. For the undecided subsample, the factors included gender, influenza vaccine, trust in the vaccine company, and perceived vaccine benefits and barriers. The results suggest that efforts of governments and health institutions should focus on women and highlight the vaccine as an opportunity to \"go back to normal\" without worries. Those results will help implement vaccine strategy in the following cases: if infant vaccination is pursued and if emergency vaccines or new vaccine technologies emerge for another pandemic as well.","PeriodicalId":392036,"journal":{"name":"The Yale Journal of Biology and Medicine","volume":" ","pages":"199-205"},"PeriodicalIF":2.7,"publicationDate":"2022-06-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/86/08/yjbm_95_2_199.PMC9235256.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40579640","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0